請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19490完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李存修 | |
| dc.contributor.author | Yi-Ta Lee | en |
| dc.contributor.author | 李易達 | zh_TW |
| dc.date.accessioned | 2021-06-08T02:01:40Z | - |
| dc.date.copyright | 2016-06-23 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-06-02 | |
| dc.identifier.citation | 1. Ablynx. (2016a). Ablynx Investors. Retrieved from http://www.ablynx.com/investors/financial-information/
2. Ablynx. (2016b). Ablynx Website. Retrieved from http://www.ablynx.com/rd-portfolio/clinical-programmes/alx-0061/ 3. Actelion. (2016a). Company news and events. Retrieved from http://www1.actelion.com/en/our-company/news-and-events.page?newsId=1483135 4. Actelion. (2016b). Corporate Fact Sheets. Retrieved from http://www1.actelion.com/documents/corporate/fact-sheets/fs-company.pdf 5. Aitken, M., and Kleinrock, M. (2014). Medicine Use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013. Parsippany, NJ: IMS Institute for Healthcare Informatics 6. Arnold, K., Coia, A., Saywell, S., Smith, T., Minick, S., and Löffler, A. (2002). Value drivers in licensing deals. Nature biotechnology, 20(11), 1085-1089. 7. Arora, A., and Fosfuri, A. (2003). Licensing the market for technology. Journal of Economic Behavior and Organization, 52, 277-295. 8. Arora, A., Fosfuri, A., and Gambardella, A. (2001). Markets for Technology: The Economics of Innovation and Corporate Strategy Cambridge, MA: MIT Press. 9. Arora, A., and Gambardella, A. (1990). Complementarity and external linkages: the strategies of the large firms in biotechnology. Journal of Industrial Economics 38, 361-379. 10. Baldi, F., and Trigeorgis, L. (2014). IP licensing: how to structure a good deal. Sinergie, 32(93), 55-78. 11. Barlas, S. (2014). Generic prices take flight: the FDA is struggling to ground them. P and T : a peer-reviewed journal for formulary management, 39(12), 833-845. 12. Behnke, N., and Hültenschmidt, N. (2007). New path to profits in biotech: Taking the acquisition exit. Journal of Commercial Biotechnology, 13, 78-85. 13. Bennett, S. (2013). Ablynx Rises on Drug Licensing Deal With AbbVie: Brussels Mover. Retrieved from http://www.bloomberg.com/news/articles/2013-09-23/ablynx-rises-on-drug-licensing-deal-with-abbvie-brussels-mover 14. Bergh, D. D., and Lim, E. N.-K. (2008). Learning how to restructure: absorptive capacity and improvisational views of restructuring actions and performance. SMJ Strategic Management Journal, 29(6), 593-616. 15. Bergström, J. L. (2010). Pharmaceutical Patent Strategies-The Competition between Originator and Generic Companies within the European Union. Jonkoping International Business School. 16. Blonigen, B. A., and Taylor, C. T. (2003). RandD Intensity and Acquisitions in High-Technology Industries: Evidence from the US Electronic and Electrical Equipment Industries. The Journal of Industrial Economics, 48(1), 47-70. 17. Chemmanur, T. J., and Yan, A. (2004). A theory of corporate spin-offs. Journal of Financial Economics, 72(2), 259-290. 18. Chen, C.-M., Sheng, T.-C., and Yang, Y.-L. (2014). Cost Efficiency Analysis of Taiwan Biotech and Pharmaceutical Industry: The Application of Stochastic Meta Frontier Model. International Journal of Economics and Finance, 6(11), p131. 19. Clift, C. (2008). The value of patent term extension to the pharmaceutical industry in the USA. J. Generic Med., 5, 201-208. 20. Cockburn, I., and Long, G. (2015). The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals. Expert Opinion on Therapeutic Patents, 25(7), 739-742. 21. Cohen, J., Gangi, W., Lineen, J., and Manard, A. (2004). Strategic Alternatives in the Pharmaceutical Industry. Retrieved from 22. CrunchBase. (2016). CrunchBase. Retrieved from https://www.crunchbase.com 23. Danzon, P., Epstein, A., and Nicholson, S. (2007). Mergers and acquisitions in the pharmaceutical and biotech industries. Managerial and Decision Economics, 28, 307-328. 24. Deeds, R. (2004). Exploration and exploitation alliances in biotechnology: a system of new product development. Strategic Management Journal 25(3), 201-221. 25. Dev, F. (2013). Drug dealers: $20 trillion of in-licensing payments. Drug Discovery Today, 18, 1027-1029. 26. DiMasi, J. A., Feldman, L., Seckler, A., and Wilson, A. (2010). Trends in risks associated with new drug development: success rates for investigational drugs. Clinical pharmacology and therapeutics, 87(3), 272-277. 27. Dimasi, J. A., and Grabowski, H. G. (2007). The cost of biopharmaceutical RandD: is biotech different? Managerial and decision economics 28(4), 469. 28. DiMasi, J. A., Grabowski, H. G., and Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of RandD costs. Journal of Health Economics, 47, 20-33. 29. Edwards, J. (2011). How GlaxoSmithKline Lost $635M in Bad Bets on Sleeping Pills. Retrieved from http://www.cbsnews.com/news/how-glaxosmithkline-lost-635m-in-bad-bets-on-sleeping-pills/ 30. EPVantage. (2013). Ablynx another beneficiary of AbbVie’s pay-to-fund approach. Retrieved from http://www.epvantage.com/Universal/View.aspx?type=Storyandid=457165andisEPVantage=yes 31. EvaluatePharma. (2014). EvaluatePharma World Preview 2014, Outlook to 2020. 32. Featherstone, J. S. R. (2004). The licensing gamble: raising the stakes. Nature Biotechnology, 3, 107-108. 33. Festel, G., and De Cleyn, S. H. (2011). RandD Spin-outs in the Pharmaceutical Industry. JOURNAL OF BUSINESS CHEMISTRY, 8(3), 101-114. 34. Finance, Y. (2016). Yahoo Finance. Retrieved from http://finance.yahoo.com/ 35. Findlay, S. M. (2007). Outsourcing in pharma. Pharmaceutical Technology Europe, 19(5), 13-14. 36. Gimv. (2013). Gimv exits biotech company Ablynx and releases resources for new investments in the biotech sector. Retrieved from http://www.gimv.com/en/media-and-news/press-releases/gimv-exits-biotech-company-ablynx-and-releases-resources-for-new-investments-in-the-biotech-sector 37. GlobalData. (2016). https://www.globaldata.com/. 38. Grabowski, H., Long, G., and Mortimer, R. (2014). Recent trends in brand-name and generic drug competition. Journal of medical economics, 17(3), 207-214. 39. Grabowski, H. G. (2007). Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective. 40. Group, B. C. (2012). BCG's Biopharmaceutical Partnering Survey-2012 Results. 41. Gulati, R. (1998). Alliances and networks. Strategic Management Journal, 19, 293-317. 42. Hess, A. M., and Rothaermel, F. T. (2011). When are assets complementary? Star scientists, strategic alliances, and innovation in the pharmaceutical industry. Strategic Management Journal, 32(8), 895-909. 43. Higgins, M. J. D. R. (2006). The outsourcing of R and D through acquisitions in the pharmaceutical industry. Journal of Financial Economics, 80, 351-383. 44. Hitt, M. A., Hoskisson, R. E., Ireland, R. D., and Harrison, J. S. (1991). Effects of Acquisitions on R and D Inputs and Outputs. The Academy of Management Journal, 34(3), 693-706. 45. Hodges, W. (2012). Five-minute focus: the pharmaceuticals industry. Retrieved from http://thegatewayonline.com/commercial-awareness/business-analysis/five-minute-focus-the-pharmaceuticals-industry 46. IMS. (2012). IMS Health. 47. IMS. (2015). World Figures 2014. Retrieved from http://www.imsconsultinggroup.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/Top_line_data/2014/World%20figures%202014.pdf 48. Kakkar, A. K. (2015). Patent cliff mitigation strategies: giving new life to blockbusters. Expert Opinion on Therapeutic Patents, 25(12), 1353-1359. 49. Kanavos, P., Costa-Font, J., and Seeley, E. (2009). Competition in off-Patent Drug Markets: Issues, Regulation and Evidence. 501-545. 50. Kapczynski, A., Park, C., and Sampat, B. (2012). Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of 'Secondary' Pharmaceutical Patents. PLoS ONE, 7(12). 51. Kresge, N. (2011). Roche Seeks ‘Targeted Acquisitions,’ Not Abbott-Sized Deal. Retrieved from http://www.bloomberg.com/news/articles/2011-10-21/roche-seeks-targeted-acquisitions-not-abbott-sized-deal 52. Krishnaswami, S., and Subramaniam, V. (1999). Information asymmetry, valuation, and the corporate spin-off decision. Journal of Financial Economics, 53(1), 73-112. 53. Lam, M. D. (2004). Dangerous liaisons. Pharmaceutical Executive, 24(5), 74. 54. LaMattina, J. (2014a). Pfizer, The Shark That Can't Stop Feeding. Retrieved from http://www.forbes.com/sites/johnlamattina/2014/05/06/major-acquisitions-now-a-necessary-part-of-pfizers-future-strategy/#1d2a93be4d0c 55. LaMattina, J. (2014b). Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different MandA Paths. Retrieved from http://www.forbes.com/sites/johnlamattina/2014/08/24/when-it-comes-to-mergersacquisitions-roche-and-pfizer-take-different-paths/#268d48ef2683 56. Lewin, K. (1998). The co-evolution of strategic alliances Organization Science, 9(3), 255-264. 57. Liao, P. J., Hsu, K. H., Lin, S. H., and Chen, Y. S. (2007). Vital Factors behind the Strategic Alliances of the Biotech Companies in Taiwan. Paper presented at the The XVII ACME International Conference on Pacific Rim Management. 58. Mastan, S. K., Thirunagari, B. L., and Sathe, B. L. (2011). The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies – an overview. CER Comparative Effectiveness Research, 1. 59. McGuire, S. (2007). Sepracor enters Lunesta marketing pact with GSK for Europe, Japan. Retrieved from http://www.mmm-online.com/channel/sepracor-enters-lunesta-marketing-pact-with-gsk-for-europe-japan/article/35641/ 60. Micklus, A. S. M. (2015). Biopharma deal-making in 2014: a record year for MandA value. Nature, 14, 84-85. 61. Mittra, J. (2007). Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms. Technology Analysis and Strategic Management, 19(3), 279-301. 62. MorningStar. (2016). MorningStar. Retrieved from http://financials.morningstar.com/ 63. Newswire, P. (2013). Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases. Retrieved from http://www.prnewswire.com/news-releases/ablynx-and-abbvie-sign-global-license-agreement-for-anti-il-6r-nanobody-alx-0061-to-treat-inflammatory-diseases-224815952.html 64. Nishimura, J., and Okada, Y. (2014). RandD portfolios and pharmaceutical licensing. Research Policy, 43(7), 1250-1263. 65. Parhankangas, A., and Arenius, P. (2003). From a corporate venture to an independent company: a base for a taxonomy for corporate spin-off firms. Research Policy Research Policy, 32(3), 463-481. 66. PharmaTimes. (2008). Actelion seals lucrative deal with GSK for insomnia drug almorexant. Retrieved from http://www.pharmatimes.com/article/08-07-14/Actelion_seals_lucrative_deal_with_GSK_for_insomnia_drug_almorexant.aspx 67. PwC. (2015a). Asia-Pacific Health Industries Newsletter. 68. PwC. (2015b). Taiwan health industries outlook. 69. Ramani, S. V., and Urias, E. (2015). Access to critical medicines: When are compulsory licenses effective in price negotiations? SSM Social Science and Medicine, 135, 75-83. 70. Roche. (2016). Roche website. Retrieved from http://www.roche.com 71. Rothaermel, F.T. (2001). Incumbent’s advantage through exploiting complementary assets via interfirm cooperation. Strategic Management Journal, 22, 687-699. 72. Schweizer, L. (2005). Organizational integration of acquired biotechnology companies in pharmaceutical companies: The need for a hybrid strategy Academy of Management Journal, 48, 1051-1074. 73. Schweizer, L. (2009). Post-merger integration of international biotechnology start-ups--The relationship between entrepreneurial strategy, culture and human resources Journal of Business Economics, 61, 133-153. 74. Service, R. F. (2004). Surviving the blockbuster syndrome. Science, 303, 1796-1799. 75. Shah, U. S. (2010). Regulatory strategies and lessons in the development of biosimilars Pharmaceutical sciences encyclopedia: Wiley. 76. Shargel, L., and Kanfer, I. (2005). Generic drug product development : solid oral dosage forms. New York: Marcel Dekker. 77. Smith, A. (2008). A new sleeping pill? Keep dreaming. Retrieved from http://money.cnn.com/2008/03/04/news/companies/insomnia1/ 78. Somaya, D., Kim, Y., and Vonortas, N. S. (2011). Exclusivity in licensing alliances: using hostages to support technology commercialization. Strategic Management Journal, 32(2), 159-186. 79. Stavropoulou, C. (2015). Compulsory licensing and access to drugs. Eur J Health Econ, 16, 83-94. 80. Thakur, V., and Ramacha, S. (2012). Pharmaceutical business strategy: A generics perspective. Journals of Intellectual Property Rights, 17(5), 484-496. 81. Tsai, W., and Erickson, S. (2006). Early-stage biotech companies: strategies for survival and growth. Biotechnology healthcare, 3(3), 49-53. 82. Wang, C.-L. J. (n.d.). Taiwan Biotech and Partnering with China Companies. Retrieved from 83. Yamanaka, T., and Kano, S. (2015). Patent term extension systems differentiate Japanese and US drug lifecycle management. Drug Discovery Today, 21(1), 111-117. 84. Ziegler, N., Gassmann, O., and Friesike, S. (2014). Why do firms give away their patents for free? World Patent Information, 37, 19-25. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19490 | - |
| dc.description.abstract | 生技醫藥產業為高風險高報酬的產業。原廠暢銷藥物(blockbuster drug)一年的銷售額可達十億美元以上，但發展這類暢銷藥物的平均成本超過5-8億美元，平均一種藥物的發展時間可達十年以上，且藥物成功上市的機率僅為5%。相對的，學名藥(generic drug)市場目前正快速發展，發展風險、時間和成本均低於原廠藥(innovator drug)，但學名藥物產品無法受到專利的保護，各學名藥廠間競爭激烈。此研究分析三個歐美生技醫藥廠所使用的發展策略(development strategy)，藉此作為台灣生技醫藥廠商的借鏡。分析結果顯示台灣生技醫藥產業的優勢在於龐大的高齡市場、高品質的醫療基礎建設、完善的人才培育及有利於產業發展的政策，但產業弱勢在於市場規模過小及資金的不足。台灣生技醫藥廠商可透過專利授權、策略聯盟、併購等方式克服以上弱勢，並適當發揮以上產業優勢。 | zh_TW |
| dc.description.abstract | The biopharmaceutical industry is a high-risk, high-return industry. Innovator blockbuster drugs can generate more than 1 billion USD annually, but average costs for developing these blockbuster drugs exceeds 500-800 million, average development times exceed ten years, and the odds of a drug successfully making it to market is less than 5%. By contrast, generic drugs can be developed quickly and with less cost, but are not covered by patent protection, and are therefore faced with more intense levels of competition. This study examines the development strategies of three global biopharmaceutical firms; our analysis results show that the advantages of Taiwanese firms lie in the expanding market for elderly care, high-quality clinical infrastructure, comprehensive training, and governmental policies beneficial for industry development. However, competitive disadvantages lie in lack of market scale and financial support. Taiwanese firms can consider utilizing their advantages and making up for their disadvantages through licensing, strategic alliance, and mergers and acquisitions. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T02:01:40Z (GMT). No. of bitstreams: 1 ntu-105-P02746028-1.pdf: 943391 bytes, checksum: daceaf91831777067b012804c9c2955e (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 中文摘要 ii
THESIS ABSTRACT iii Contents iv List of Figures v List of Tables vi 1. Introduction 1 1.1 Background 1 1.2 Study Purpose 2 1.3 Outline 3 2. Literature Review 5 2.1 The Pharmaceutical Industry 5 2.2 Innovator and Generic Companies 13 2.3 Growth Strategies 17 3. Case Studies of Strategic Growth 28 3.1 Licensing 29 3.2 Strategic Alliance 31 3.3 Mergers and Acquisitions 33 4. Strategic Analysis 37 4.1 Market Characteristics 37 4.2 Case Analysis 39 4.3 Overall Analysis 44 5. Conclusion 48 References 50 | |
| dc.language.iso | en | |
| dc.title | 台灣生技醫藥廠商發展策略之探討 | zh_TW |
| dc.title | A Study of Growth Strategies for Biopharmaceutical Companies in Taiwan | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 陳思寬 | |
| dc.contributor.oralexamcommittee | 陳業寧 | |
| dc.subject.keyword | 生技產業,醫藥產業,生技醫藥產業,藥廠,策略, | zh_TW |
| dc.subject.keyword | biotechnology industry,pharmaceutical industry,biopharmaceuticals,strategy,drug companies, | en |
| dc.relation.page | 57 | |
| dc.identifier.doi | 10.6342/NTU201600293 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2016-06-03 | |
| dc.contributor.author-college | 管理學院 | zh_TW |
| dc.contributor.author-dept | 國際企業管理組 | zh_TW |
| 顯示於系所單位： | 國際企業管理組 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 目前未授權公開取用 | 921.28 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。